News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Horizon Pharma, Inc. Announces Pricing of Its Initial Public Offering


7/28/2011 8:51:38 AM

NORTHBROOK, IL--(Marketwire - July 28, 2011) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a price to the public of $9.00 per share. Horizon's common stock is scheduled to begin trading on The NASDAQ Global Market on July 28, 2011 under the symbol "HZNP." Horizon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares at the initial public offering price to cover overallotments, if any.

Stifel Nicolaus Weisel, Cowen and Company and JMP Securities LLC are acting as joint bookrunners for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 28, 2011. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,11717, Phone (631) 274-2806 / Fax (631) 254-7140; or JMP Securities LLC, 600 Montgomery Street, Suite 1100, San Francisco, CA 94111, or by calling (415) 835-8985.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Horizon Pharma
Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. For more information, please visit www.horizonpharma.com.


Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Email Contact

Media
Geoff Curtis
Invigorate PR
312-646-6298
Email Contact

Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES